Gennecs: an Egyptian success story shaping biologics production at home and beyond

20 March 2023

Research-based Egyptian pharma company Gennecs Pharmaceuticals, part of the Gennecs group, belongs to the El Daba Holding Group, a trading conglomerate serving Egypt and the countries of the Gulf Cooperation Council that partners with local and international investors.

The group, including Gennvax facility, is the local and regional representative of more than 10 top global pharmaceutical manufacturers and distributors in Egypt, forming the biggest vaccines portfolio in the Middle East and North Africa (MENA) region.

Its portfolio includes several top global vaccines as well as sera and biotech products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK